1 Min Read
April 20 (Reuters) - Abeona Therapeutics Inc:
* ABEONA THERAPEUTICS RECEIVES ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR ABO-202 GENE THERAPY PROGRAM IN BATTEN DISEASE Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.